Deal targets muscular dystrophy, heart failure suffered by muscular dystrophy patients, and hemophilia B.
Asklepios Biopharmaceutical entered into a cross license agreement with GlaxoSmithKline to develop and commercialize gene therapy-based treatments.
Through the agreement, AskBio will gain exclusive access to selected recombinant adeno-associated virus vector serotypes that GSK licensed from the University of Pennsylvania for the treatment of three orphan drug indications, including muscular dystrophy, heart failure suffered by muscular dystrophy patients, and hemophilia B.
